Greenwich Lifesciences公司宣布,其Flamingo-01试验的指导委员会已正式批准增加研究规模,并全力推进患者招募加速进程。
这一决定旨在更快地积累临床数据,为试验的后续推进提供更坚实的支持。加速入组有望缩短整体研究时间线。
公司对指导委员会的支持表示欢迎,并认为此举将优化试验执行效率。市场密切关注该生物技术公司核心管线的进展。
Greenwich Lifesciences公司宣布,其Flamingo-01试验的指导委员会已正式批准增加研究规模,并全力推进患者招募加速进程。
这一决定旨在更快地积累临床数据,为试验的后续推进提供更坚实的支持。加速入组有望缩短整体研究时间线。
公司对指导委员会的支持表示欢迎,并认为此举将优化试验执行效率。市场密切关注该生物技术公司核心管线的进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.